CDKN2B and central nervous system cancer: Across brain tumor subtypes, such as glioblastoma and low-grade glioma, differences in mutation rates showed the same trend in eight driver events among C1/2 subtypes, including CDKN2A/CDKN2B and PTEN deletion, IDH mutation, and co-deletion of 1p and 19q (Figure S7).